Viatris (VTRS) Competitors $8.88 -0.39 (-4.21%) Closing price 04:00 PM EasternExtended Trading$8.94 +0.05 (+0.62%) As of 07:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock VTRS vs. PFE, ARGX, ONC, BNTX, INSM, SMMT, TEVA, ITCI, GMAB, and MRNAShould you be buying Viatris stock or one of its competitors? The main competitors of Viatris include Pfizer (PFE), argenex (ARGX), BeOne Medicines (ONC), BioNTech (BNTX), Insmed (INSM), Summit Therapeutics (SMMT), Teva Pharmaceutical Industries (TEVA), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), and Moderna (MRNA). These companies are all part of the "medical" sector. Viatris vs. Its Competitors Pfizer argenex BeOne Medicines BioNTech Insmed Summit Therapeutics Teva Pharmaceutical Industries Intra-Cellular Therapies Genmab A/S Moderna Viatris (NASDAQ:VTRS) and Pfizer (NYSE:PFE) are both large-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, earnings, media sentiment, profitability, dividends, valuation, analyst recommendations and institutional ownership. Is VTRS or PFE a better dividend stock? Viatris pays an annual dividend of $0.48 per share and has a dividend yield of 5.4%. Pfizer pays an annual dividend of $1.72 per share and has a dividend yield of 7.0%. Viatris pays out -15.1% of its earnings in the form of a dividend. Pfizer pays out 124.6% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Pfizer has raised its dividend for 16 consecutive years. Pfizer is clearly the better dividend stock, given its higher yield and longer track record of dividend growth. Do insiders & institutionals believe in VTRS or PFE? 79.9% of Viatris shares are held by institutional investors. Comparatively, 68.4% of Pfizer shares are held by institutional investors. 0.1% of Viatris shares are held by insiders. Comparatively, 0.1% of Pfizer shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Is VTRS or PFE more profitable? Pfizer has a net margin of 12.62% compared to Viatris' net margin of -26.45%. Pfizer's return on equity of 20.33% beat Viatris' return on equity.Company Net Margins Return on Equity Return on Assets Viatris-26.45% 16.20% 7.01% Pfizer 12.62%20.33%8.53% Does the media prefer VTRS or PFE? In the previous week, Pfizer had 66 more articles in the media than Viatris. MarketBeat recorded 81 mentions for Pfizer and 15 mentions for Viatris. Viatris' average media sentiment score of 1.20 beat Pfizer's score of 0.67 indicating that Viatris is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viatris 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 8 Negative mention(s) 0 Very Negative mention(s) Positive Pfizer 52 Very Positive mention(s) 4 Positive mention(s) 18 Neutral mention(s) 4 Negative mention(s) 2 Very Negative mention(s) Positive Which has higher earnings and valuation, VTRS or PFE? Pfizer has higher revenue and earnings than Viatris. Viatris is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioViatris$14.74B0.71-$634.20M-$3.17-2.80Pfizer$63.63B2.19$8.03B$1.3817.72 Do analysts recommend VTRS or PFE? Viatris presently has a consensus price target of $10.40, suggesting a potential upside of 17.12%. Pfizer has a consensus price target of $28.55, suggesting a potential upside of 16.72%. Given Viatris' higher possible upside, analysts plainly believe Viatris is more favorable than Pfizer.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Viatris 2 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.80Pfizer 1 Sell rating(s) 13 Hold rating(s) 5 Buy rating(s) 3 Strong Buy rating(s) 2.45 Which has more volatility and risk, VTRS or PFE? Viatris has a beta of 0.89, meaning that its share price is 11% less volatile than the S&P 500. Comparatively, Pfizer has a beta of 0.58, meaning that its share price is 42% less volatile than the S&P 500. SummaryPfizer beats Viatris on 14 of the 20 factors compared between the two stocks. Get Viatris News Delivered to You Automatically Sign up to receive the latest news and ratings for VTRS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VTRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VTRS vs. The Competition Export to ExcelMetricViatrisMedical Services IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.88B$6.78B$5.52B$9.41BDividend Yield5.18%2.87%3.80%4.04%P/E Ratio-2.8026.7728.0419.84Price / Sales0.7135.79429.5399.59Price / Cash1.8226.7235.8457.94Price / Book0.579.028.125.65Net Income-$634.20M$233.10M$3.25B$258.00M7 Day Performance-2.63%-0.15%0.97%2.09%1 Month Performance1.25%1.22%7.36%11.13%1 Year Performance-24.55%23.83%31.31%18.40% Viatris Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VTRSViatris3.2683 of 5 stars$8.88-4.2%$10.40+17.1%-21.7%$10.88B$14.74B-2.8032,000Trending NewsPFEPfizer4.9618 of 5 stars$25.36-1.2%$28.55+12.6%-18.1%$144.15B$62.46B18.3781,000Trending NewsARGXargenex4.4966 of 5 stars$561.28+0.2%$728.06+29.7%+23.6%$34.35B$2.25B34.631,599Positive NewsAnalyst RevisionONCBeOne Medicines2.5583 of 5 stars$252.14+0.7%$320.67+27.2%N/A$27.63B$3.81B-67.7811,000Analyst ForecastGap UpBNTXBioNTech1.4591 of 5 stars$111.00-1.7%$137.91+24.2%+28.4%$26.68B$2.98B-32.656,772Analyst ForecastINSMInsmed3.8659 of 5 stars$101.89+3.8%$108.07+6.1%+37.9%$19.33B$381.03M-17.121,271Positive NewsAnalyst ForecastInsider TradeSMMTSummit Therapeutics2.886 of 5 stars$25.40+1.6%$34.67+36.5%+196.8%$18.86BN/A-74.70110TEVATeva Pharmaceutical Industries4.1195 of 5 stars$16.43+0.2%$24.71+50.5%-0.4%$18.84B$16.54B-14.2836,830ITCIIntra-Cellular Therapies0.9225 of 5 stars$131.87flat$109.70-16.8%N/A$14.05B$680.50M-151.57560GMABGenmab A/S3.9168 of 5 stars$21.46+0.3%$37.80+76.1%-18.0%$13.77B$3.12B12.192,682Analyst RevisionMRNAModerna4.2835 of 5 stars$32.88-2.3%$46.61+41.8%-74.0%$12.72B$3.24B-3.775,800Trending NewsOptions VolumeAnalyst Revision Related Companies and Tools Related Companies Pfizer Alternatives argenex Alternatives BeOne Medicines Alternatives BioNTech Alternatives Insmed Alternatives Summit Therapeutics Alternatives Teva Pharmaceutical Industries Alternatives Intra-Cellular Therapies Alternatives Genmab A/S Alternatives Moderna Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VTRS) was last updated on 7/18/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredFREE BUY ALERT: These 3 tiny AI stocks could surgeWe're living in unprecedented times. Most people think it's too late to get into AI right now … That the...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Viatris Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Viatris With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.